Up 91% in the Past Year, Is This Biotech Stock Red Hot or a Red Flag?

• Puma Biotechnology (PBYI) relies on one product. It has weak fundamentals and has struggled to grow sales.
• PBYI stock has surged 91% over the past year, driven by technical momentum and speculative trading spikes.
• Despite technical “Buy” signals, analyst sentiment is mixed, with most rating PBYI as “Hold” or “Sell.”
• With stagnant revenue, declining earnings, and only one product, PBYI lacks compelling long-term investment appeal.

Today’s Featured Stock